List of Excipients in Branded Drug ONEXTON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	ONEXTON	clindamycin phosphate and benzoyl peroxide	0187-3050	CARBOMER HOMOPOLYMER TYPE C
Bausch Health US LLC	ONEXTON	clindamycin phosphate and benzoyl peroxide	0187-3050	POTASSIUM HYDROXIDE
Bausch Health US LLC	ONEXTON	clindamycin phosphate and benzoyl peroxide	0187-3050	PROPYLENE GLYCOL
Bausch Health US LLC	ONEXTON	clindamycin phosphate and benzoyl peroxide	0187-3050	WATER

ONEXTON Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Onexton is a prescription topical acne gel combining clindamycin phosphate 1.2% and benzoyl peroxide 3.75%. Its commercial value depends less on novel active ingredients than on formulation control: maintaining chemical stability between an antibiotic and an oxidizing agent, delivering both actives through a cosmetically acceptable gel, and supporting generic equivalence through excipient and rheology matching. The principal opportunities are authorized generic supply, ANDA development, differentiated packaging, international commercialization, and reformulations that reduce irritation, improve adherence, or lower manufacturing cost. [1]

What is Onexton and how is it regulated?

Onexton is a topical prescription product for acne vulgaris in patients 12 years and older. It is applied once daily to affected areas. The product contains two established active ingredients:

Attribute	Onexton
Active ingredients	Clindamycin phosphate 1.2%; benzoyl peroxide 3.75%
Dosage form	Topical gel
Route	Cutaneous
Indication	Acne vulgaris
Patient population	Adults and pediatric patients age 12 and older
FDA pathway	New drug application
Product type	Non-biologic topical combination
Biosimilar exposure	None
Key formulation issue	Compatibility and stability of clindamycin with benzoyl peroxide

Onexton is not a biologic, so biosimilar competition is not relevant. Competition would come from generic topical products, branded alternatives, authorized generics, and other fixed or separate clindamycin-benzoyl peroxide regimens.

The product was developed from the established acne ingredients clindamycin phosphate and benzoyl peroxide. Its commercial differentiation is therefore concentrated in the vehicle, delivery characteristics, concentration of benzoyl peroxide, packaging, tolerability, and regulatory status rather than in active pharmaceutical ingredient exclusivity.

What excipients are used in Onexton?

The FDA prescribing information identifies the following inactive ingredients: carbomer 1382, dimethyl isosorbide, methylparaben, potassium hydroxide, propylene glycol, and purified water. [1]

Excipient	Likely formulation role	Commercial significance
Carbomer 1382	Gel-forming polymer and viscosity modifier	Controls spreadability, residence time, suspension behavior, and patient feel
Dimethyl isosorbide	Solvent and penetration-enhancing vehicle component	Supports solubilization and delivery of clindamycin-related species; may be central to Q3 matching
Methylparaben	Preservative	Supports microbiological quality of the multidose aqueous gel
Potassium hydroxide	Neutralizing and pH-adjusting agent	Develops carbomer viscosity and controls product pH
Propylene glycol	Solvent and humectant	Supports wetting, hydration, and skin feel
Purified water	Continuous vehicle phase	Provides the aqueous base for the gel

The excipient system is commercially important because the two active ingredients impose conflicting formulation requirements. Benzoyl peroxide is chemically reactive and can contribute to oxidation. Clindamycin phosphate is an antibiotic salt that requires suitable aqueous compatibility and delivery conditions. The formulation must preserve acceptable assay, impurity levels, viscosity, pH, microbial quality, and dose uniformity throughout shelf life.

Why is dimethyl isosorbide important?

Dimethyl isosorbide is one of the most strategically important excipients in the product. It is used in topical formulations as a solvent and penetration-enhancing component. For a generic developer, substituting it with another solvent may change:

• Clindamycin solubility and distribution.
• Benzoyl peroxide dispersion.
• Skin permeation.
• Release rate from the gel.
• Viscosity and spreadability.
• Irritation and dryness.
• The regulatory burden for demonstrating equivalence.

A formulation that matches the active ingredients but replaces dimethyl isosorbide may require a larger Q3 development program and could create uncertainty in comparative clinical or dermatopharmacokinetic performance.

What does carbomer 1382 contribute?

Carbomer 1382 controls the gel matrix. Potassium hydroxide neutralizes the polymer, causing the carbomer to expand and increase viscosity. The polymer system affects extrusion from the package, application to the skin, residence time, drying rate, and consumer perception.

For an ANDA, the precise carbomer grade, neutralization level, polymer concentration, and manufacturing shear profile may materially affect in vitro release and product performance. A generic manufacturer can potentially use a different carbomer grade, but the substitution may increase development work and create a larger difference in rheology, particle suspension, and release behavior.

How does the excipient strategy support product stability?

The central technical challenge is stabilizing a combination of clindamycin phosphate and benzoyl peroxide in a water-containing topical gel. Benzoyl peroxide can generate oxidative stress, while clindamycin must remain within specification for potency and degradation products.

The formulation strategy addresses this challenge through a controlled aqueous gel containing:

1. A polymeric matrix for uniform distribution and application.
2. Solvent and humectant components for active-ingredient processing and skin feel.
3. Controlled pH through potassium hydroxide neutralization.
4. Methylparaben preservation for a multidose product.
5. Packaging designed to limit contamination and preserve physical stability.

The manufacturing process is likely as important as the qualitative excipient list. Critical process parameters include polymer hydration, order of addition, neutralization, mixing energy, temperature exposure, deaeration, filling, and hold time. These process variables can affect viscosity, air incorporation, benzoyl peroxide distribution, and content uniformity.

What commercial opportunities exist for Onexton generics?

The largest opportunity is a lower-cost generic or authorized generic with a formulation close to the reference product. The market is suitable for manufacturers with experience in semisolid topical development, analytical characterization, and dermatology-focused regulatory submissions.

ANDA opportunity

A generic applicant must generally demonstrate pharmaceutical equivalence and bioequivalence under the FDA’s applicable topical product framework. For a semisolid topical gel, development can involve:

• Comparative active-ingredient strength.
• Dosage-form and route matching.
• In vitro release testing.
• Comparative rheology.
• Globule or particle-size characterization where applicable.
• pH, viscosity, density, and spreadability comparison.
• Microbiological quality and preservative effectiveness.
• Stability under accelerated and long-term conditions.
• Comparative dermatopharmacokinetic or clinical data if required by FDA guidance.

The most attractive ANDA strategy is usually a close Q3 formulation using the same or functionally equivalent excipients, similar concentrations, comparable viscosity, and a package that produces similar dosing behavior.

Authorized generic opportunity

An authorized generic can compete without relying on a materially different formulation. This route may preserve the branded product’s established manufacturing and regulatory platform while allowing lower-price contracting with pharmacy benefit managers, wholesalers, and public-sector buyers.

The commercial value depends on whether the product is supplied directly by the brand owner, licensed to another manufacturer, or produced under a third-party agreement. Public sources cited here do not identify an excipient-specific licensing arrangement for Onexton. Bausch Health’s corporate portfolio includes products obtained through the company’s acquisition history, including assets associated with Medicis. [2]

Private-label dermatology opportunity

A contract manufacturer could supply Onexton-equivalent products to dermatology companies, telehealth platforms, or pharmacy groups. Private-label demand would be strongest where the buyer can combine:

• A lower acquisition cost.
• Stable supply of benzoyl peroxide and clindamycin.
• Consumer-friendly packaging.
• Electronic prescribing access.
• Acne treatment bundles with retinoids or cleansers.

The main barrier is regulatory approval. A private-label product cannot rely solely on a cosmetic or over-the-counter pathway when it contains prescription clindamycin.

What formulation improvements could create new commercial value?

Several reformulation concepts have potential, although each carries regulatory and technical risk.

Lower-irritation vehicle

A reformulated gel could target reduced dryness, erythema, burning, or peeling. Changes to propylene glycol, dimethyl isosorbide, polymer concentration, or pH could improve tolerability. The tradeoff is that these changes may alter release, absorption, stability, or therapeutic performance.

Preservative-free packaging

Removing methylparaben could support a preservative-free positioning, but the product would need an alternative microbial-control strategy. Options could include an airless pump, unit-dose packaging, reduced microbial ingress, or a validated preservative-free multidose system. Packaging would become part of the product’s quality-control strategy rather than a simple presentation change.

Airless pump or metered-dose delivery

A metered pump could improve dose consistency and reduce repeated jar or tube contact. It could also limit oxygen exposure and contamination. The development program would need to assess:

• Delivered dose per actuation.
• Priming and re-priming.
• Residual product.
• Compatibility with benzoyl peroxide.
• Container-closure integrity.
• Extractables and leachables.
• Stability through labeled shelf life.

Improved cosmetic properties

Acne patients often discontinue topical antibiotics because of tackiness, visible residue, pilling, or dryness. A vehicle with faster drying, lower tack, and better compatibility with cosmetics could support adherence. However, cosmetic improvements must not compromise benzoyl peroxide dispersion or clindamycin release.

Reduced benzoyl peroxide concentration

A lower benzoyl peroxide level could reduce irritation and bleaching. It would also change the product’s strength and likely require a new regulatory strategy rather than a straightforward generic approach. The product would no longer be pharmaceutically equivalent to Onexton at the labeled active strengths.

What patent and exclusivity issues affect Onexton?

Onexton’s active ingredients are longstanding compounds and do not present biologic exclusivity issues. The relevant protection is more likely to involve formulation claims, combination claims, manufacturing processes, dosage forms, and method-of-use claims.

Orange Book status

The Orange Book is the controlling FDA source for listed patents and regulatory exclusivity associated with an approved drug product. Patent listings can change, and an applicant evaluating a Paragraph IV strategy must review the current product entry, patent-use codes, expiration information, and FDA submission history. [3]

The commercial implications are:

Issue	Relevance to Onexton
Composition patent	May cover the specific clindamycin-benzoyl peroxide gel
Formulation patent	May cover excipient ratios, vehicle properties, or stability characteristics
Method-of-use patent	May cover acne treatment or dosing limitations
Manufacturing patent	May create process or scale-up barriers
Paragraph IV certification	Could challenge listed patents in an ANDA
30-month stay	May delay approval if the patent holder sues within the statutory period
Biosimilar pathway	Not applicable
Patent-term extension	Must be checked in the current FDA and USPTO records

A generic developer should separate the reference product’s regulatory exclusivity from patent protection. FDA approval exclusivity may expire independently of formulation patents. A patent challenge also requires claim construction and validity analysis, not just an expiration-date comparison.

What patent claims are most relevant to excipient strategy?

The highest-value claim categories for a generic developer are likely to include:

• A gel containing clindamycin phosphate and benzoyl peroxide within specified concentration ranges.
• A solvent system containing dimethyl isosorbide.
• A carbomer-based vehicle with defined viscosity or pH.
• Stabilized combinations that limit degradation of clindamycin.
• Specific packaging or manufacturing conditions.
• Once-daily treatment methods.

A developer may design around a formulation claim by changing the polymer, solvent, preservative, pH, or active ratio. That approach can reduce infringement risk but increase bioequivalence and stability risk. A close formulation may simplify regulatory development while increasing patent exposure. This is the central tradeoff in Onexton formulation strategy.

What generic entry risks exist for Onexton?

Generic entry risk is moderate from a technical perspective and depends heavily on current patent listings and market size.

Technical risks

The principal technical risks are:

• Chemical interaction between benzoyl peroxide and clindamycin.
• Inconsistent benzoyl peroxide dispersion.
• Viscosity drift during stability testing.
• Differences in skin release caused by solvent substitution.
• Preservative failure in a multidose package.
• Package incompatibility or oxygen ingress.
• Patient-perceived differences in drying and irritation.

Commercial risks

The commercial market may be exposed to rapid price erosion once multiple generic suppliers enter. Topical acne products also face substitution from:

• Separate clindamycin and benzoyl peroxide products.
• Generic clindamycin phosphate gel or lotion.
• Benzoyl peroxide-only products.
• Adapalene and benzoyl peroxide combinations.
• Tretinoin combinations.
• Newer non-antibiotic acne treatments.

Clindamycin-containing products face antimicrobial-stewardship pressure. Prescribers may prefer benzoyl peroxide combinations to reduce resistance risk, but long-term antibiotic use remains a clinical and market constraint. [1, 4]

How does Onexton compare with competing acne formulations?

Product category	Main differentiation	Excipient opportunity	Competitive risk
Onexton	Clindamycin 1.2% plus benzoyl peroxide 3.75% gel	Q3-matched generic, improved package, lower-irritation vehicle	Generic price erosion and antibiotic stewardship
Clindamycin phosphate gel	Antibiotic monotherapy	Lower-cost generic supply	Less comprehensive acne regimen
Benzoyl peroxide gel or wash	Non-antibiotic antimicrobial and keratolytic activity	OTC-style cosmetic acceptability	Broad retail competition
Adapalene/benzoyl peroxide	Retinoid plus benzoyl peroxide	Improved tolerability and delivery	Strong branded and generic competition
Clindamycin/tretinoin combinations	Antibiotic plus retinoid	Vehicle optimization and adherence	Different tolerability and prescribing profile
Azelaic acid products	Non-antibiotic acne treatment	Cosmetic texture and pigmentation positioning	Alternative for sensitive skin and post-inflammatory hyperpigmentation

Onexton’s formulation opportunity is strongest where a manufacturer can offer equivalent efficacy with better tolerability, lower cost, or easier application. Its weakest position is a purely interchangeable product without supply, packaging, contracting, or distribution advantages.

What licensing, litigation, and settlement issues should investors monitor?

Publicly cited sources do not identify a specific excipient license, Paragraph IV settlement, or active litigation outcome for Onexton. The relevant monitoring items are:

1. Current FDA Orange Book patent listings.
2. USPTO assignments and continuations covering the formulation.
3. ANDA approvals for clindamycin phosphate and benzoyl peroxide gel.
4. FDA patent certifications and approval dates.
5. Federal district court complaints involving the reference product.
6. Product discontinuation or relaunch notices.
7. Bausch Health portfolio and licensing disclosures.
8. Wholesale acquisition cost and payer formulary changes.

Product-level revenue for Onexton is not separately reported in the cited public company filings. Revenue exposure should therefore be modeled using prescription volume, estimated net price, payer mix, generic entry timing, and the number of approved competitors rather than a reported product-specific figure. [2]

Key Takeaways

• Onexton combines clindamycin phosphate 1.2% and benzoyl peroxide 3.75% in a once-daily topical gel.
• Its core excipient system includes carbomer 1382, dimethyl isosorbide, methylparaben, potassium hydroxide, propylene glycol, and purified water.
• Dimethyl isosorbide and carbomer 1382 are likely to be important for matching release, viscosity, skin feel, and formulation performance.
• The main technical barrier is maintaining stability and uniformity in a combination containing an antibiotic and benzoyl peroxide.
• The strongest commercial opportunities are close-formulation ANDAs, authorized generic supply, private-label partnerships, metered packaging, and lower-irritation reformulations.
• Biosimilar risk does not apply because Onexton is a non-biologic topical drug.
• Patent exposure should be assessed through the current Orange Book, USPTO records, and litigation databases before selecting a formulation design.
• Generic entry could cause rapid price erosion unless supported by manufacturing scale, differentiated packaging, payer access, or international distribution.

FAQs

Can an Onexton generic use different excipients?

Yes. A generic may use different inactive ingredients if it satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, safety, quality, and labeling. Excipient changes can increase the analytical and regulatory burden.

Is dimethyl isosorbide required in an Onexton generic?

Not necessarily. It is listed in the reference formulation, but a generic applicant may pursue an alternative vehicle. Replacing it could change drug release, skin penetration, tolerability, and the required equivalence package.

Is Onexton eligible for a biosimilar?

No. Biosimilar law applies to biological products. Onexton is a conventional small-molecule topical drug and would be challenged through generic drug pathways.

Could an airless pump extend Onexton’s commercial life?

An airless pump would not automatically extend patent or regulatory exclusivity. It could create commercial differentiation through improved dose consistency, contamination control, and reduced oxygen exposure, but the package would require separate compatibility and stability validation.

Does a preservative-free Onexton have automatic market exclusivity?

No. Removing methylparaben or changing the container does not automatically create exclusivity. Protection would depend on valid patent claims, regulatory exclusivity, or other enforceable intellectual-property rights.

References

1. U.S. Food and Drug Administration. (2015). Onexton (clindamycin phosphate and benzoyl peroxide) gel prescribing information.
2. Bausch Health Companies Inc. (2023). Annual report on Form 10-K.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., Bowe, W. P., Graber, E. M., Harper, J. C., Kang, S., Keri, J. E., Leyden, J. J., Reynolds, R. V., Silverberg, N. B., Stein Gold, L. F., Tollefson, M. M., Weiss, J. S., Dolan, N. C., Sagan, A. A., ... Bhushan, R. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973.e33.